Natera, Inc. $NTRA Shares Bought by Groupama Asset Managment

Groupama Asset Managment grew its stake in Natera, Inc. (NASDAQ:NTRA) by 3.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,061 shares of the medical research company’s stock after purchasing an additional 2,805 shares during the period. Groupama Asset Managment’s holdings in Natera were worth $19,011,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in NTRA. Oddo BHF Asset Management Sas purchased a new position in shares of Natera during the 1st quarter valued at approximately $6,410,000. Bull Harbor Capital LLC acquired a new position in shares of Natera in the 1st quarter valued at $1,543,000. Encore Global Management LP purchased a new stake in Natera during the first quarter worth $1,200,000. Royal Bank of Canada boosted its holdings in Natera by 18.1% during the first quarter. Royal Bank of Canada now owns 288,069 shares of the medical research company’s stock worth $57,611,000 after buying an additional 44,077 shares in the last quarter. Finally, Eversept Partners LP grew its position in Natera by 15.0% during the first quarter. Eversept Partners LP now owns 384,713 shares of the medical research company’s stock valued at $76,939,000 after buying an additional 50,220 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $267.76 on Friday. The firm has a market cap of $38.35 billion, a PE ratio of -164.27 and a beta of 1.51. The firm has a fifty day moving average of $246.77 and a 200 day moving average of $222.22. Natera, Inc. has a one year low of $131.81 and a one year high of $288.04.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NTRA. BTIG Research set a $275.00 price objective on shares of Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. William Blair began coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating on the stock. Royal Bank Of Canada began coverage on Natera in a research note on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target for the company. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the transaction, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 173,951 shares of company stock valued at $39,412,294. Insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.